Novabay Pharmaceuticals (NBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,504 | 9,028 | 10,294 | 10,508 | 11,952 |
| Receivables | 1,668 | 843 | 1,232 | 1,038 | 1,106 |
| Inventories | 3,220 | 969 | 682 | 850 | 608 |
| TOTAL | $13,170 | $11,497 | $12,772 | $13,146 | $14,242 |
| Non-Current Assets | |||||
| PPE Net | 193 | 96 | 94 | 100 | 84 |
| Intangibles | 9,728 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 887 | 646 | 737 | 826 | 912 |
| TOTAL | $10,808 | $742 | $831 | $926 | $996 |
| Total Assets | $23,978 | $12,239 | $13,603 | $14,072 | $15,238 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,045 | 1,354 | 208 | 833 | 302 |
| Accrued Expenses | 2,092 | 1,325 | 1,883 | 1,851 | 2,115 |
| TOTAL | $3,442 | $2,874 | $2,389 | $3,080 | $2,833 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 10,365 | 1 | 5 | 9 | 87 |
| TOTAL | $10,365 | $1 | $5 | $9 | $87 |
| Total Liabilities | $13,807 | $2,875 | $2,394 | $3,089 | $2,920 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 42 | 37 | 37 | 34 | 34 |
| Common Shares | 478 | 450 | 447 | 418 | 418 |
| Retained earnings | -141,887 | -141,729 | -139,440 | -137,581 | -136,063 |
| Other shareholders' equity | 680 | 0 | 0 | 0 | 0 |
| TOTAL | $10,171 | $9,364 | $11,209 | $10,983 | $12,318 |
| Total Liabilities And Equity | $23,978 | $12,239 | $13,603 | $14,072 | $15,238 |